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and Samuel Klein1,2
ABSTRACT
Background: Obesity is associated with an increased prevalence and severity of infections.
The mechanism(s) responsible for the increased risk of infections is unclear. We evaluated
the effects of excessive adiposity and weight loss on peripheral blood mononuclear cell
(PBMC) chemokine (macrophage chemoattractant protein-1 [MCP-1) and cytokine (interferon-
 [IFN-]) production, which is an important component of the immune response to infec-
tious pathogens. Methods: Lipopolysaccharide (LPS)- and phorbol 12-myristate 13-acetate plus
ionomycin (PMAI)-stimulated PBMC MCP-1 and IFN- production were determined in six
extremely obese subjects (body mass index [BMI]  62.4  8.6 kg/m2) before and 1 year after
gastric bypass surgery and in six age-matched lean subjects (BMI  22.7  1.4 kg/m2). Results:
At baseline, LPS-stimulated MCP-1 production and PMAI-stimulated IFN- production by
PBMCs were 93.6%  4.9% and 88.8%  9.6% lower, respectively, in obese than in lean sub-
jects (p  0.03). Obese subjects lost 30.3%  10.6% of their body weight at 1 year after gastric
bypass surgery (p  0.001). Weight loss completely restored LPS-stimulated MCP-1 produc-
tion and PMAI-stimulated IFN- production in obese subjects to normal. Conclusions: Ag-
onist-stimulated production of IFN- and MCP-1 are markedly suppressed in subjects with
extreme obesity. Weight loss completely normalizes the ability of stimulated PBMCs to pro-
duce MCP-1 and IFN-. These findings could have important implications in understanding
the increased risk of infections associated with obesity, and demonstrate a unique beneficial
effect of weight loss on immune function.
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INTRODUCTION
OBESITY IS ASSOCIATED WITH an increasedprevalence and severity of local and sys-
temic infections. Obesity increases the risk of
nosocomial systemic and wound infections af-
ter general,1–5 gastrointestinal,6 cardiac,7,8 or-
gan transplantation,9 and knee replacement
surgery,10 and after serious burn injury.11 The
mechanism(s) responsible for the increased risk
of infections is not known, but likely involve
alterations in immune system function, includ-
ing impairment of polymorphonuclear and
natural killer cells killing function, and lower
capacity of lymphocytes to proliferate in re-
sponse to mitogen activation.12–14
Cytokines and chemokines, produced by ac-
tivated circulating mononuclear cells, help di-
1Division of Geriatrics and Nutritional Sciences and 2Center for Human Nutrition, Washington University School
of Medicine, St. Louis, Missouri.
3Division of Food Science, Human Nutrition and Health, Istituto Superiore di Sanitá, Rome, Italy.
rect the immune response needed for optimal
protection against foreign pathogens. Chemo-
kines, such as macrophage chemoattractant
protein-1 (MCP-1), are essential for accumulat-
ing and activating neutrophils and macro-
phages at infectious foci, whereas cytokines,
such as interferon- (IFN-), increase the abil-
ity of macrophages and cytotoxic T cells to 
kill infectious pathogens.15 Mice deficient in
MCP-1 or IFN- are killed by normally sub-
lethal doses of bacteria and viruses.16,17
The purpose of the present study was to eval-
uate the hypothesis that peripheral blood
mononuclear cell (PBMC) immune function in
extremely obese adults is impaired, but that
weight loss can improve defective PBMC ac-
tivity. Lipopolysaccharide (LPS)-stimulated
and phorbol 12-myristate 13-acetate plus iono-
mycin (PMAI)-stimulated PBMC cytokine
and chemokine production were determined in
lean subjects and in extremely obese subjects
before and 1 year after marked weight loss in-
duced by gastric bypass surgery.
MATERIALS AND METHODS
Study subjects
Six women with class III obesity (body mass
index [BMI]  40 kg/m2) and six age-matched
lean women participated in this study. Subjects
completed a comprehensive medical evalua-
tion, which included a history and physical ex-
amination, an electrocardiogram, and standard
blood and urine tests. All subjects reported that
they were weight stable ( 2% change in body
weight) and sedentary ( 1 hour regular exer-
cise per week) for at least 2 months before base-
line studies were performed. Each subject 
provided written, informed consent before par-
ticipating in this study, which was approved
by the Human Studies Committee and the Gen-
eral Clinical Research Center (GCRC) Scientific
Advisory Committee of Washington Univer-
sity School of Medicine in St. Louis, Missouri.
Experimental protocol
After subjects fasted overnight (12 hours),
blood samples were obtained by venipuncture
from an antecubital vein. Blood samples were
taken from the lean group on one occasion, and
from the obese group before and 1 year after
marked weight loss, induced by gastric bypass
surgery. Peripheral blood was taken directly
into sterile ethylenediaminetetraacetic acid
(EDTA)-containing vacutainer tubes. Mononu-
clear cells were isolated by using Histopaque-
1077 (Sigma Chemical Co., St. Louis, MO) den-
sity gradient centrifugation, washed two times
in pyrogen-free saline, resuspended in RPMI
1640 (supplemented with 0.3 mg/mL L-gluta-
mine, 100 U/mL penicillin, 100 g/mL strep-
tomycin) with 10% sterile homologous human
serum, and seeded in flat-bottom multiwell
dishes (Costar, Cambridge, MA) at a concen-
tration of 1  106 cells/mL. Cells were then in-
cubated (humidified 5% CO2, 37°C) for 24
hours without agonist, with LPS endotoxin (1
ng/mL), or with PMA (20 ng/mL) plus iono-
mycin (500ng/mL) (Sigma). We stimulated hu-
man PBMCs with PMA plus ionomycin
(PMAI) to preferentially activate T and nat-
ural killer (NK) cells, and with LPS to prefer-
entially activate monocytes, even if these stim-
uli are not ideal, because LPS can activate
lymphocytes and PMA can activate monocytes.
Nonetheless, the stimuli we used still allowed
us to distinguish between cell types, because
MCP-1 is produced by monocytes, while IFN-
 is primarily produced by TH1 CD4 T cells,
CD8 T cells, and NK cells. Cell supernatants
were obtained by centrifugation and stored at
70°C until subsequent analyses.
Sample analyses
Serum and supernatant MCP-1 and IFN-
were measured by using Luminex™ technol-
ogy (LINCO Research, Inc., St. Charles, MO).
Serum insulin and leptin concentrations were
determined by using radioimmunoassay
(LINCO Research, Inc.).
Statistical analyses
The statistical significance of differences be-
tween measurements obtained in lean and
obese subjects at baseline and in measurements
obtained in lean subjects at baseline and in
obese subjects 1 year after surgery were evalu-
ated by using a Student’s t test for unpaired
samples. The statistical significance of differ-
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ences between longitudinal measurements ob-
tained at baseline and 1 year after surgery in
obese subjects were assessed by using a Stu-
dent’s t test for paired samples. All reported 
p values are two-sided, and a value of  0.05
was considered to be statistically significant.
All data were analyzed by using SPSS for 
Windows software, version 12.0 (SPSS Inc.,
Chicago, IL).
RESULTS
Body weight and metabolic characteristics
Body weight and BMI were much greater in
obese than lean subjects, and decreased by
30.3%  10.6% after bariatric surgery in the
obese group (p  0.001; Table 1). Serum insulin
and leptin concentrations were much greater in
obese than lean subjects at baseline, and de-
creased after bariatric surgery in the obese group
(p  0.01; Table 1). Serum MCP-1 and IFN- con-
centrations were not different between lean and
obese subjects, and did not change after weight
loss in the obese group. One year after gastric
bypass surgery, plasma glucose concentration
had decreased from 125  32 to 81  8 mg/dL
(p  0.01), plasma low-density lipoprotein
(LDL)-cholesterol concentration from 115  40
to 86  23 mg/dL (p  0.05), and plasma triglyc-
eride concentration from 146  24 to 94  22
mg/dL (p  0.01).
PBMC chemokine and cytokine production
The production of MCP-1 and IFN- by un-
stimulated PBMC were not different between
lean and obese subjects, either at baseline or at
1 year after gastric bypass surgery; when
PBMCs were incubated without agonist, MCP-
1 concentrations were 73  74, 62  59, and
65  18 pg/mL, and IFN- concentrations
were were 1.4  0.8, 1.0  0.5, and 1.4  0.9
pg/mL for lean subjects, obese subjects at 
baseline, and obese subjects 1 year after gastric
bypass surgery, respectively. However, LPS-
stimulated MCP-1 production and PMAI-
stimulated IFN- production by PBMCs were
93.6%  4.9% and 88.8%  9.6% lower, respec-
tively, in obese subjects than in lean subjects at
baseline (p  0.03; Fig. 1). Bariatric surgery-
induced weight loss markedly increased LPS-
stimulated MCP-1 and PMAI-stimulated
IFN- production to values that were not sig-
nificantly different from baseline lean values.
DISCUSSION
Obesity is associated with an increased risk
of infection,1–11 but the mechanism(s) respon-
sible for this relationship is not clear. We hy-
pothesized that obesity might have adverse ef-
fects on cytokine and chemokine production by
PBMCs, which are important components of
the immune system response to infectious or-
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Lean subjects Baseline gastric bypass surgery
Weight (kg) 62.5  6.9 166.4  23a 116.1  25b
BMI (kg/m2) 22.7  1.4 62.4  8.6a 43.7  10b
Insulin (U/mL) 3.8  2.2 28.1  23a 7.3  6.1c
Leptin (ng/mL) 9  5 63  16a 37  11c
MCP-1 (pg/mL) 365  68 414  241 469  326
IFN- (pg/mL) 9.8  0.7 11.1  2.3 9.8  0.4
Values are means 6 standard deviation (SD).
aValue significantly different from corresponding lean group value, p  0.01.
Value significantly different from corresponding obese group baseline values, 
bp  0.001, cp  0.001.
BMI, body mass index; MCP-1, macrophage chemoattractant protein-1; IFN-, inter-
feron-.
ganisms. The results of the present study dem-
onstrate that although basal PBMC cytokine
(i.e., IFN-) and chemokine (i.e., MCP-1) pro-
duction are the same in lean and extremely
obese persons, PMAI-stimulated production
of IFN- and LPS-stimulated production of
MCP-1 are markedly suppressed by obesity.
However, weight loss completely restored the
ability of stimulated PBMCs to produce MCP-
1 and IFN- to normal. These data suggest that
obesity is associated with considerable abnor-
malities in mononuclear cell immune function,
but these abnormalities are completely re-
versible with weight loss.
Our data indicate that activated PBMC se-
cretion of two key immune modulators, IFN-
and MCP-1, is almost completely suppressed
in extremely obese patients. MCP-1 promotes
monocyte migration into sites of inflammation,
where monocytes differentiate into macro-
phages or dendritic cells.15,18 IFN- is involved
in activating macrophage phagocytosis and
generating bactericidal mediators, such as re-
active oxygen species and nitric oxide.19 In ad-
dition, IFN- promotes antigen presentation by
dendritic cells and activates polymorphonu-
clear (PMN) leukocytes.15,17,19 MCP-1 is also in-
volved in regulating IFN- production; mice
lacking the MCP-1 receptor have a profound
defect in IFN- production.20 Therefore, our
data suggest that obesity is associated with se-
vere defects in both innate and adaptive im-
mune responses.
Several other abnormalities in immune cell
function have been identified in obese persons.
Obesity is associated with a decreased capac-
ity of lymphocytes to proliferate in response to
mitogen activation13,14 and impaired polymor-
phonuclear leukocyte bactericidal capacity.12
These data, in conjunction with the results of
the present study, demonstrate that obesity is
associated with multiple defects in white blood
cell functions, which can impair the host re-
sponse to an attack from pathogenic organisms
and likely contribute to the increased preva-
lence of infections observed in obese patients.
We found that weight loss normalized MCP-
1 and IFN- production by activated PBMCs.
Although our study cannot determine the
mechanism responsible for this improvement,
several factors could be involved. First, it is
possible that weight loss decreases obesity-in-
duced PBMC insulin and leptin resistance, and
thereby normalize MCP-1 and IFN- produc-
tion. This notion is supported by data demon-
strating that insulin and leptin are involved in
T-lymphocyte metabolism. Insulin receptor ex-
pression and signaling in T lymphocytes after
in vitro stimulation are decreased in obese sub-
jects,21–23 which could impair lymphocyte glu-
cose uptake and cytokine production.24 Leptin-
deficient mice and humans have impaired T
cell proliferation, phagocytosis, and cytokine
production, which are normalized by leptin 
administration.25–27 Second, weight loss can
decrease plasma IL1-Ra concentration, which
could increase PBMC cytokine-induced pro-
FONTANA ET AL.44
FIG. 1. Lipopolysaccharide (LPS)-stimulated macro-
phage chemoattractant protein-1 (MCP-1) production (A)
and phorbol 12-myristate 13-acetate plus ionomycin
(PMAI)-stimulated interferon- (IFN-) production (B)
by peripheral blood mononuclear cells (PBMCs) in 6 lean
and in 6 extremely obese subjects before and 1 year after
marked weight loss induced by gastric bypass surgery.
†Significantly different from lean value (p  0.03); *Sig-
nificantly different from baseline obese value (p  0.03).
Values are means  standard error (SE).
B
A
duction of MCP-1 and IFN-.28 Third, weight
loss can decrease serum IL-10 concentrations,
which would inhibit both monocyte and lym-
phocyte proinflammatory cytokine produc-
tion.29 Fourth, weight loss-induced changes in
blood glucose and lipids could have improved
phagocyte and lymphocyte function, which are
impaired by high blood glucose and lipid con-
centrations.30
The results from our study identify an ap-
parent paradox in immune function in obese
persons. Obesity is associated with increased
inflammation, manifested by an upregulation
of cytokine and chemokine production by adi-
pose tissue, presumably from both adipocytes
and infiltrated macrophages.31–33 At the same
time, obesity is associated with a defective im-
mune response to infection, manifested by a
downregulation of stimulated cytokine and
chemokine production by circulating mononu-
clear cells. Overactivity of the immune system
during basal conditions is harmful because it is
likely to contribute to insulin resistance, dia-
betes, and coronary heart disease,31,33 whereas
underactivity of the immune response to inva-
sive pathogens is also harmful because it is
likely to increase host vulnerability to infec-
tious agents. Weight loss normalizes both ab-
normalities by decreasing the production of cy-
tokines and chemokines by adipose tissue34,35
and increasing their production by PBMCs
when challenged by infectious agents. These
findings underscore the complex relationship
between obesity and the immune system. Ad-
ditional studies are needed to identify the pre-
cise mechanisms responsible for the profound
effects of adiposity on immune function.
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